SNBL and Tasso, Inc. to Establish Joint Venture in Japan

TOKYO and KAGOSHIMA, Japan (March 28, 2025 JST) / SEATTLE, Washington, USA (March 27, 2025 PT) – Shin Nippon Biomedical Laboratories, Ltd. (TSE Prime: 2395, Representative Chairman, President & CEO: Ryoichi Nagata, M.D., Ph.D.; hereinafter “SNBL”) and Tasso, Inc., the Seattle-based leading provider of patient-centric, clinical grade blood collection solutions (Co-founder & CEO: Ben Casavant, Ph.D.; hereinafter “Tasso”) hereby announce that they have agreed to establish a new joint venture company (hereinafter “JV”) for exclusive distribution of Tasso’s proprietary on-demand blood collection device in Japan.

The establishment of the JV between SNBL and Tasso aims to contribute to important themes in Japan, such as self-medication, preventative medicine, telemedicine, and reducing the burden on medical professionals (particularly doctors and nurses), by leveraging the unique features of Tasso's self-blood collection device: (1) it enables a painless collection, (2) it can be used anywhere, including at home, (3) it can be self-administered, and (4) it collects high-quality blood samples using a compatible collection tube.

The JV has the exclusive right to sell Tasso products in Japan, and will manage and oversee the regulatory process, commercialization (including promotion, marketing and sales), and distribution of the device in Japan.

“As part of the SGG initiative, we aim to support the growth of Japanese companies that are aiming to enter the US market and US companies that are planning to enter the Japanese market, and to create new business opportunities for both sides. We believe that this JV is an initiative based on the SGG concept and will make a significant contribution to the improvement of clinical experience,” said Dr. Ryoichi Nagata, Representative Chairman, President & CEO of SNBL.

SGG refers to the SNBL Global Gateway (SGG) project, which makes the most of the strong network of SNBL's CRO and translational research (TR) businesses, which have been cultivated over many years, centered on our facilities in Washington State, USA, and maximizes the use of SNBL’s strong network of Japanese and American academia, investors, and professional companies.

"We are pleased to partner with SNBL as part of the SGG initiative. SNBL’s expertise will streamline the entry of Tasso’s virtually painless blood collection technology to the Japanese market, enabling a better patient experience for Japan," said Ben Casavant, PhD, CEO and Co-Founder of Tasso.

Inquiries

Shin Nippon Biomedical Laboratories, Ltd.

IR & Corporate Communications

Email: ir@snbl.com

Tasso, Inc.

Media Relations

Email: media@tassoinc.com

Tasso Surpasses 1.5 Million Devices Sold: A Look Back at Recent Milestones

2024 was a landmark year for Tasso as we advanced our mission to make diagnostic testing more accessible and enhance the patient experience. With over 1.5 million devices sold, our innovative, patient-centric blood collection technology continues to transform the healthcare industry. 

As we move further into 2025, Tasso remains at the forefront of the shift toward better patient experiences, reinforcing our commitment to deliver accessible diagnostics that empower clinicians and patients to make informed decisions. 

To our partners and employees — whether in commercial, community, or clinical settings — we deeply value your collaboration. Together, we are driving innovation, improving patient care, and reaching new heights. 

With this milestone as a backdrop, now is the perfect time to reflect on some of Tasso’s recent achievements. 

Driving Innovation in Blood Collection Technology 

Tasso introduced its next-generation dried blood spot (DBS) sample collection technology, a major step forward in sampling for clinical trials and sports anti-doping testing. The novel collection system combines Tasso’s newly announced Tile™-T20 dried whole blood cartridge with a Tasso™ Mini device, enabling the precise, convenient collection of DBS samples. By prioritizing ease of use and reliability alongside technological advances, we continue to redefine the patient experience in blood collection. 

Shedding Light on Patient Experience and Access Challenges in Healthcare 

A Tasso-commissioned survey revealed that one in three patients delay diagnostic blood testing due to anxiety, pain, and inconvenience — barriers that can lead to missed routine care and delayed diagnoses. Our work continues to focus on solving these challenges by providing an accessible, virtually painless alternative that fits patient lifestyles. 

Forging Strategic Partnerships for Broader Impact 

Tasso announced its partnership with ARUP Laboratories to enhance and accelerate decentralized clinical research. This collaboration combines our virtually painless, convenient blood collection technology with ARUP’s leading biomarker testing capabilities for a superior end-to-end testing option. By integrating our capabilities, clinical researchers now have a streamlined solution to collect high-quality samples remotely while maintaining gold standard test accuracy and reliability. 

Strengthening Security and Compliance 

Tasso successfully renewed its SOC 2 Type II compliance certification, reinforcing our commitment to the highest standards of data security and privacy. As remote blood collection becomes an integral part of clinical trials and decentralized healthcare, maintaining trust and regulatory compliance remains a top priority. 

Tasso Announces Next Generation Technology for Patient-Centric Dried Blood Spot Sample Collection

New collection system modernizes the dried blood spot patient experience for clinical trials and has the potential to improve trial timelines, speed drug development

SEATTLE – February 11, 2025 – Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced the launch of its next generation technology for dried blood spot (DBS) sample collection. The novel collection system combines Tasso’s new Tile™-T20 dried whole blood cartridge with a Tasso™ Mini device, enabling the precise, convenient collection of DBS samples for clinical trials and sports anti-doping testing.

Tasso’s new collection system provides advantages over legacy DBS methods, improving and accelerating the clinical trial process. Tile-T20 is the first DBS collection cartridge designed specifically for use with patient-centric blood lancets. Tile-T20 collects four precise, volumetrically-controlled blood samples that meet the needs of quantitative endpoints or drug concentration measurements. It is compatible with any of Tasso’s virtually painless, FDA-cleared and CE Marked blood collection devices, including Tasso Mini and Tasso+®.

Tasso Mini is the latest device in Tasso’s signature line of patient-centric blood lancets, providing a gentle collection experience ideal for use with sensitive populations or for applications that may require more frequent blood draws. The Tasso Mini device is FDA Class II Lancet 510(k)-cleared and CE Marked.

“Dried blood samples offer many advantages for clinical trials and remote applications, but collection methods have long been a burden on patients, relying on painful finger sticks and messy blood spotting to obtain samples,” said Ben Casavant, PhD, CEO and Co-Founder of Tasso. “Our next generation dried blood collection systems enable a better patient experience alongside new process improvements.”

“Access to clinic sites can be difficult for many patients, especially for those without reliable transportation or living in rural areas. Unfortunately, access challenges often lead to recruitment and retention issues, ultimately delaying clinical trial timelines,” said Erwin Berthier, PhD, CTO and Co-Founder of Tasso. “This new technology has the potential to improve trial timelines and speed new therapies to patients in need.”

To learn more about Tasso’s dried blood collection solutions, please visit  www.tassoinc.com/dried-blood.

About Tasso

Tasso is an emerging healthcare technology company that is transforming the traditional blood collection paradigm with a patient-centric approach. The company’s devices enable simple, convenient, and virtually painless blood collection for users. Tasso technology has the power to bring healthcare anywhere, any time. Headquartered in Seattle, Washington, Tasso is privately held and funded by grants, investments, and co-development deals with various industry leaders. For more information, please visit www.tassoinc.com.

Media Contact

Dina Schneider

(206) 822-4186 x1016

media@tassoinc.com

Tasso and ARUP Laboratories Announce Partnership, Combined Offering for Decentralized Clinical Research Biomarker Testing

Partnership combines Tasso’s clinical grade blood collection solutions and ARUP’s gold standard testing capabilities to streamline and accelerate decentralized clinical research

SEATTLE and SALT LAKE CITY, February 3, 2025 – Tasso Inc., the leading provider of patient-centric, clinical grade blood collection solutions, and ARUP Laboratories, the largest nonprofit clinical and academic reference laboratory in the United States, today announced that they have entered into a partnership to develop and operationalize high-quality, at-home, blood testing services to support clinical research. By providing the testing component of the new combined offering, ARUP Laboratories brings the trusted expertise of more than 100 medical directors and offers more than 3,000 laboratory tests and test combinations that are prequalified by most pharmaceutical companies, ensuring simple operationalization of the service and streamlined clinical research.  

“Patient-centric testing solutions are needed to provide better access to clinical research and enable the development of personalized or predictive blood testing solutions,” said Erwin Berthier, PhD, chief technology officer and cofounder of Tasso. “Tasso combining forces with ARUP Laboratories, a trusted industry leader, enables us to provide gold standard remote testing solutions that remove barriers to adoption of decentralized testing.”

To launch the partnership, ARUP has validated rheumatoid factor (RF), high-sensitivity C-reactive protein (hsCRP), creatinine, and high-sensitivity DNA testing using capillary blood microsamples collected with Tasso devices. Additional assays and applications will be made available throughout 2025 and beyond as validation protocols are completed. These tests will be powered by Tasso’s end-to-end services platform that includes novel shipping solutions and digital patient-facing solutions to ensure successful blood collection and logistics.

“Advancing diagnostic solutions that better address the needs of health systems and patients is at the core of ARUP’s mission,” said Tracy George, MD, ARUP chief scientific officer and president of ARUP’s Innovation Business Unit. “By developing testing that is compatible with Tasso’s game-changing remote blood collection solutions, we will further increase participant access to clinical research.”

ARUP has extensive experience in supporting clinical research with unparalleled service and robust, quality testing. Test development and validation are supported by the expertise of ARUP’s medical directors, all of whom are members of the faculty in the Department of Pathology at the University of Utah’s Spencer Fox Eccles School of Medicine.

About Tasso

Tasso is an emerging healthcare technology company that is transforming the traditional blood collection paradigm with a patient-centric approach. The company’s devices enable simple, convenient, and virtually painless blood collection for users. Tasso technology has the power to bring healthcare anywhere, any time. Headquartered in Seattle, Washington, Tasso is privately held and funded by grants, investments, and codevelopment deals with various industry leaders. For more information, please visit www.tassoinc.com.

About ARUP Laboratories

Founded in 1984, ARUP Laboratories is a leading national reference laboratory and a nonprofit enterprise of the University of Utah Spencer Fox Eccles School of Medicine and its Department of Pathology. ARUP offers more than 3,000 tests and test combinations, ranging from routine screening tests to esoteric molecular and genetic assays. In addition, ARUP is a worldwide leader in innovative laboratory research and development, led by the efforts of the ARUP Institute for Research and Innovation in Diagnostic and Precision Medicine™. ARUP is ISO 15189 and CAP accredited. For more information, visit www.aruplab.com.

Media Contacts

Tasso

Dina Schneider

206-822-4186 ext. 1016

media@tassoinc.com

ARUP

Bonnie Stray

801-583-2787 ext. 2823

media@aruplab.com

Tasso Announces Renewal of SOC 2 Type II Compliance Certification

Completion of SOC 2 Type II audit certifies the continued security of Tasso platforms  

SEATTLE – November 12, 2024 – Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced the successful renewal of their SOC 2 Type II compliance certification with an unqualified opinion, also known as a clean report, following a rigorous independent audit. The SOC 2 Type II audit is conducted by independent, third-party auditors to determine whether a company is maintaining enterprise-level data security through its operations, controls, and processes. This renewal highlights Tasso’s continuing commitment to meeting the highest industry standards and demonstrates the company’s ability to securely manage client data. 

The audit was conducted by Prescient Assurance, a leader in security and compliance attestation for B2B and SaaS companies worldwide. 

Tasso provides a variety of end-to-end logistics services as part of its Tasso Care® blood collection solutions platform. Renewal of SOC 2 Type II compliance certification, the industry gold standard, ensures that client data is safe across Tasso’s online platforms and API. 

“Tasso is committed to protecting sensitive patient data at the highest industry standards,” said Ben Casavant, PhD, CEO and Co-Founder of Tasso. “This SOC 2 Type II renewal demonstrates our continued commitment to security and privacy across our platforms.” 

About Tasso 

Tasso is an emerging healthcare technology company that is transforming the traditional blood collection paradigm with a patient-centric approach. The company’s devices enable simple, convenient, and virtually painless blood collection for users. Tasso technology has the power to bring healthcare anywhere, any time. Headquartered in Seattle, Washington, Tasso is privately held and funded by grants, investments, and co-development deals with various industry leaders. For more information, please visit www.tassoinc.com. 

Media Contact 

Dina Schneider 

(206) 822-4186 x1016 

media@tassoinc.com 

Tasso, Inc.’s Survey Unveils One in Three Patients Delay Diagnostic Blood Tests — Anxiety, Pain and Inconvenience of Traditional Phlebotomy Lead to Patients Missing Routine Care

78% Of Patients Reported That Having Blood Drawn Induces Anxiety

74% Of Patients Interested in Technology That Allows Painless Blood Collection at Home

SEATTLE – October 17, 2024 – Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, surveyed more than 600 adults (age 18-65+) within the United States to assess their experiences and preferences regarding blood testing, as well as their perspectives about the future of patient care. The survey, titled Patient Preferences, Perceptions, and the Evolving Challenges of Ensuring Patient Compliance With Diagnostic Healthcare Testing, validated prevailing industry perspectives that the current status quo for blood collection underserves patients seeking more convenient and less painful options for blood collection.

Laboratory test results influence approximately 70% of medical decisions, according to the U.S. Centers for Disease Control and Prevention, highlighting the need to make testing more accessible. However, the survey revealed that one in three patients delay or avoid diagnostic blood tests, with the top reasons being inconvenient testing locations and discomfort during blood collection. Notably, 37% of respondents cited a fear of needles, a significant barrier to completing these essential tests.

The survey also found that 73% of respondents have purchased a home health testing kit, particularly during the peak of the COVID-19 pandemic, yet only 15% of respondents have completed a home blood test, suggesting that patients have low familiarity with what home testing options are available to them.  Modern technologies that enable the self-collection of clinical-grade blood samples are expanding the possibilities of moving healthcare into the home, however, patient preferences and perceptions relating to home blood testing must be understood to successfully drive broader adoption of home-based care programs.

"This survey validated our assumption that the painful and often inconvenient process of blood collection frequently leads to patient non-compliance and missed care," said Ben Casavant, PhD, CEO and Co-Founder of Tasso. "Disrupting this model is crucial, as routine blood tests can detect critical health changes early. While patients are more familiar with home testing post-COVID, few have had access to home blood test kits. Offering a painless, at-home option could significantly improve compliance, especially for those with limited access to healthcare facilities."

Additional findings include:

Patients are not willing to travel far for blood testing and may put off physician-prescribed tests if the process is inconvenient.

Access to blood testing can be difficult for many patients, especially for those without reliable transportation and those living in rural areas. Not surprisingly, access challenges lead patients to delay prescribed testing.

• 69% are unwilling to travel more than 10 miles from home to complete a blood test

• The #1 reported reason for delaying a prescribed blood test is that patients find it difficult to schedule time for a clinic visit

Patients associate pain and anxiety with traditional phlebotomy blood collection

Simply put, patients dislike having their blood drawn by venipuncture. Fear of needles is a significant factor. The majority of respondents report feelings of anxiety about the blood draw process and that they experience pain during the collection.

• 78% of respondents report some level of anxiety associated with having their blood drawn

• 37% of respondents report a fear of needles

• 87% of respondents rate their physical pain from venipuncture blood collection as a 1 or above on a standard 1-10 pain scale

Clear demand for solutions that improve the patient blood collection experience

Patients are seeking solutions to improve their blood testing experience and are willing to pay out of pocket for them.

• Of those respondents who rated pain associated with venipuncture blood collection, 76% are willing to pay out of pocket to reduce the pain level

• 74% of respondents are interested in using painless home blood collection technology to complete a prescribed blood test

• When asked to explain their interest in taking healthcare tests with a painless home blood collection technology, the #1 reason was painlessness and the #2 reason was convenience.

Methodology

The survey was conducted by PureSpectrum, an independent market research platform that gathers insights via its consumer Insights Platform in conjunction with an in-house sample Marketplace Platform. This Insights project studied 606 consumers between June 05, 2024 and June 24, 2024.

About Tasso

Tasso is an emerging healthcare technology company that is transforming the traditional blood collection paradigm with a patient-centric approach. The company’s devices enable simple, convenient, and virtually painless blood collection for users. Tasso technology has the power to bring healthcare anywhere, any time. Headquartered in Seattle, Washington, Tasso is privately held and funded by grants, investments, and co-development deals with various industry leaders. For more information, please visit www.tassoinc.com.

Media Contact

Dina Schneider
(206) 822-4186 x1016
media@tassoinc.com

InnoVero and Tasso Extend Partnership Providing Athlete-Centric Solutions for Anti-Doping Testing

Industry innovators will continue collaborating on virtually painless, secure anti-doping technologies

COLORADO SPRINGS, CO and SEATTLE – July 9, 2024 – InnoVero, a global leader in providing innovative, athlete-centric collection technologies to anti-doping organizations worldwide and Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced the extension of their partnership that was first initiated in 2021. In addition to collaboratively developing new athlete-centric solutions, InnoVero will continue to serve as the exclusive worldwide distributor of Tasso blood collection solutions for the anti-doping marketplace.

As part of the InnoVero SAFESystem™ product suite, the companies have co-developed a secure, intuitive, and virtually painless system for anti-doping blood testing. The system features Tasso’s signature capillary blood collection technology, which frees athletes from the inconvenience of traditional blood tests such as venipuncture or fingerstick collections. The combined offering, which has been well-received by key stakeholders, including athletes, doping control officers, administrators, and laboratories, continues to see expanded utilization across anti-doping testing programs globally. Professional and Olympic and Paralympic sports organizations, as well as major international sporting events, such as the upcoming Paris 2024 Olympic Games, have quickly realized the advantages of this athlete-centric technology.

“Our partnership with Tasso is helping us deliver on our promise to drive innovation and integrity in anti-doping products. Tasso’s signature capillary blood collection technology has significantly improved the blood collection process providing an efficient, easy-to-implement, and athletic-centric solution” said Gabe Baida, Executive Director of InnoVero. “The response to our Tasso-based collection system from athletes and anti-doping organizations has been very positive. We are pleased to extend our partnership with Tasso and excited to continue developing innovative solutions together at the forefront of anti-doping technology.”

“The extension of our partnership with InnoVero demonstrates the strong demand for athlete-centric solutions,” said Ben Casavant, PhD, CEO and Co-Founder of Tasso. “Tasso’s virtually painless blood collection technology, combined with InnoVero’s leading security innovations, empowers athletes to focus on their performance and trust in a level playing field. Together, InnoVero and Tasso will continue to improve anti-doping testing for athletes everywhere.”

About InnoVero

InnoVero provides innovation and integrity to the global anti-doping community, through solutions designed to secure global athlete trust. InnoVero’s SAFESystem™ sample collection solutions serve clients globally, The SAFESystem™ features revolutionary security mechanisms that ensure its sample collection bottles are secure, athlete-friendly and tamper-evident, among a suite of features designed to provide seamless and efficient use by athletes, doping control officers and laboratories. For more information about InnoVero, please visit www.innoveroglobal.com.

About Tasso

Tasso is an emerging healthcare technology company that is transforming the traditional blood collection paradigm with a patient-centric approach. The company’s devices enable simple, convenient, and virtually painless blood collection for users. Tasso technology has the power to bring healthcare anywhere, any time. Headquartered in Seattle, Washington, Tasso is privately held and funded by grants, investments, and co-development deals with various industry leaders. For more information, please visit www.tassoinc.com.

Media Contacts

InnoVero

Brad Horn

(512) 636-3831

bhorn@innoveroglobal.com

Tasso, Inc.

Dina Schneider

(206) 822-4186 x1016

media@tassoinc.com

Lindus Health and Tasso Establish Collaboration to Streamline Clinical Trials Through Remote Blood Collection

NEW YORK, NY and SEATTLE – June 4, 2024 – Lindus Health, the “anti-CRO” running radically faster, more reliable clinical trials for life science pioneers, and Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced a new collaboration that will reduce patient burden in clinical trials requiring blood collection. Lindus Health will adopt Tasso’s virtually painless remote blood collection technology as an option for sponsors looking to enable simple, more cost-effective remote blood collection while conducting their clinical trials. This innovative method will allow participants to collect simple blood samples themselves at home without the need for a mobile phlebotomist or nurse.

Logistical factors are common barriers to study participation. The inclusion of Tasso minimizes these by reducing, and sometimes even eliminating, lengthy study visits and travel to and from physical sites with their solution that allows clinical trial participants to collect blood from the comfort of their own homes, without the added expense and logistics of mobile phlebotomy/nursing. Tasso remote blood sampling technologies have the capabilities to increase the reach and diversity of clinical trials whilst reducing patient burden and associated dropout rates. Clinical trial participants will receive Tasso’s blood collection device along with prepaid shipping materials to easily ship their samples for analysis.

Tasso’s clinical grade blood collection technology is preferred by 9 out of 10 participants over a fingerstick or phlebotomy. By offering a more convenient way of performing blood draws in clinical research, sponsors can anticipate higher rates of patient recruitment and retention in their studies, ultimately reducing timelines to achieve enrollment targets. 

"Partnering with Tasso provides Lindus Health with a cutting-edge tool for remote blood collection, significantly expediting the clinical trial process,” said Michael Young, Co-Founder of Lindus Health. “This collaboration enables us to design more flexible and patient-centric trials, ensuring greater convenience and participation. Together, we are accelerating the delivery of new treatments to patients, transforming the landscape of medical research."

“Patients are at the heart of clinical trials,” said Ben Casavant, PhD, CEO and Co-Founder of Tasso. “Making blood collection a better experience can bolster patient engagement, ultimately leading to trials that recruit and complete faster. We are pleased to partner with fellow innovator Lindus Health to accelerate life-saving clinical studies.” 

The integration of Tasso’s at-home blood collection into Lindus Health’s sample collection services, enables enhanced, more cost-effective data collection and encourages the adoption of patient-centric practices in clinical research.

About Lindus Health

Lindus Health is an anti-CRO running radically faster and more reliable trials for life science pioneers – bringing ground-breaking treatments to patients more quickly. This is achieved through a commercial model that aligns incentives (fixed-priced quotes per study, with milestone-based payments), a world-class clinical operations team with its unique software platform, and access to over 30 million Electronic Health Records. 

Clinical trials are the biggest bottleneck to advances in healthcare. Lindus Health removes this constraint by handling the end-to-end execution of clinical studies, including design, patient recruitment, clinical data capture, monitoring and project management.

To date, Lindus Health has delivered more than 90 trials across the US, UK and Europe to tackle a range of conditions, including diabetes, asthma, acne, social anxiety, major depressive disorder, hypertension, chronic fatigue syndrome and insomnia. The company has raised over $24M from investors including Peter Thiel, CREANDUM, Firstminute Capital, Presight Capital, Seedcamp, Hambro Perks, Amino Collective and Calm/Storm.

About Tasso

Tasso is an emerging healthcare technology company that is transforming the traditional blood collection paradigm with a patient-centric approach. The company’s devices enable simple, convenient, and virtually painless blood collection for users. Tasso technology has the power to bring healthcare anywhere, any time. Headquartered in Seattle, Washington, Tasso is privately held and funded by grants, investments, and co-development deals with various industry leaders. For more information, please visit www.tassoinc.com.

Media Contacts

Lindus Health

Jodi Perkins Amendola 

jperkins@acmarketingpr.com 

Tasso, Inc.

Dina Schneider

(206) 822-4186 x1016

media@tassoinc.com

The Leukemia & Lymphoma Society and Tasso Announce Partnership to Advance Blood Cancer Research

First collaboration is a clinical trial evaluating patient-centric methodologies for Complete Blood Count (CBC) analysis

RYE BROOK, N.Y. and SEATTLE – May 30, 2024 – The Leukemia & Lymphoma Society® (LLS), a global leader in the fight against blood cancer, and Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced a collaboration to accelerate blood cancer research. The relationship will combine Tasso’s signature capillary blood collection technology with LLS’ research and focus on patient advocacy, with the goal of improving the oncology patient experience.

Frequent clinic visits and venipuncture blood draws are a burden on patients with leukemia, lymphoma, and other blood cell disorders. The effort of traveling to a distant clinic site for monitoring can be difficult for an ill patient, while in-person visits can present dangers for immunocompromised individuals. To reduce the burden on blood cancer patients, LLS and Tasso are collaborating on a clinical trial evaluating a new patient-centric strategy for collecting critical Complete Blood Count (CBC) using the Tasso device in blood cancer patients with low blood counts.

 “This study is creating a new frontier of what is possible with remote capillary blood collection technologies,” said Erwin Berthier, PhD, CTO and Co-Founder of Tasso.  The clinical trial will compare blood samples collected with a Tasso device to the current standard of care requiring a venous draw. Tasso devices are virtually painless to use and can collect samples remotely, driving patient engagement by eliminating the travel and discomfort burdens associated with traditional blood testing.

“As a true patient-centric organization, The Leukemia & Lymphoma Society seeks out innovations that can make receiving care easier for blood cancer patients,” said Ashley Yocum, PhD, Executive Research Strategy Lead of the Beat AML® Master Clinical Trial at LLS. “Our ongoing partnership with Tasso will accelerate the adoption of clinical trial protocols that put patients first.”

“Making blood testing accessible for patients is the key to driving new research and therapies,” said Ben Casavant, PhD, CEO and Co-Founder of Tasso. “We are proud to partner with LLS on this important mission to improve and accelerate oncology research.”

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society® (LLS) is the global leader in the fight against blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease, and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.

Founded in 1949 and headquartered in Rye Brook, NY, LLS has regions throughout the United States and Canada. To learn more, visit www.LLS.org. Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m. ET.

For additional information, visit lls.org/lls-newsnetwork. Follow us on Facebook, Twitter, and Instagram. 

About Tasso

Tasso is an emerging healthcare technology company that is transforming the traditional blood collection paradigm with a patient-centric approach. The company’s devices enable simple, convenient, and virtually painless blood collection for users. Tasso technology has the power to bring healthcare anywhere, any time. Headquartered in Seattle, Washington, Tasso is privately held and funded by grants, investments, and co-development deals with various industry leaders. For more information, please visit www.tassoinc.com.

Media Contacts

The Leukemia & Lymphoma Society

Ryan McDonald

mediarelations@lls.org

Tasso, Inc.

Dina Schneider

(206) 822-4186 x1016

media@tassoinc.com

Parkinson’s Foundation and Tasso Announce Partnership to Accelerate Parkinson’s Disease Genetics Research

The Parkinson’s Foundation research study powered by Tasso’s patient-friendly blood collection technology enables broad participation and testing

NEW YORK, MIAMI, AND SEATTLE – April 23, 2024 – The Parkinson’s Foundation and Tasso, Inc. today announced a partnership to expand and accelerate genetic research into Parkinson’s disease (PD). The partnership leverages Tasso’s patient-centric, end-to-end sample collection and logistics platform to enable data collection for a landmark international genetics study by the Parkinson’s Foundation: PD GENEration: Mapping the Future of Parkinson’s.

Beginning this month, PD GENEration participants will receive a kit containing a Tasso device to collect a small blood sample in the comfort and convenience of their home. Live on-line proctors will guide participants through the painless collection process and provide support to promote successful collection. After collection, participants will be able to ship their sample in a pre-paid box to an accredited laboratory for analysis. The goal of the research is to screen the collected samples for mutations among select, clinically relevant PD genes.

“Tasso and the Parkinson’s Foundation share a mission to accelerate life-changing research,” said Ben Casavant, PhD, CEO and co-founder of Tasso. “Ensuring study participation is accessible and approachable for PD patients is critical to success. We are proud to partner with the Parkinson’s Foundation to enable a better research experience for people living with PD.”

PD GENEration tests for mutations among select, clinically relevant genes to accelerate research, to advance treatments, and to improve care for those living with PD. The study aims to make genetic testing accessible to every person with PD, empowering people with the disease and their physicians to know their genetic status and identify clinical trials in which they might enroll. PD GENEration returns genetic results to all participants through a genetic counseling session, building a critical bridge between people with PD and clinicians to accelerate research collectively.

“The data shared from PD GENEration will drive scientific research forward and improve the understanding of Parkinson’s disease,” said James Beck, PhD, Senior Vice President and Chief Scientific Officer of the Parkinson’s Foundation. “With Tasso as our partner, we now have a viable platform to enable our ambitious goal of whole-genome sequencing, which offers a promising pathway to better understand the genetics of PD and to facilitate research toward new therapies for PD.”

Tasso’s patented blood collection technology is preferred by users for its painless collection process, which is easy for participants or their care partners to complete. Participants may complete the process entirely from the comfort of their own home.

The study is sponsored by the Parkinson’s Foundation with support from the Global Parkinson's Genetics Program (GP2), a program of the Aligning Science Across Parkinson's (ASAP) initiative. ASAP is managed by the Coalition for Aligning Science and implemented by the Michael J. Fox Foundation. Additional information about PD GENEration is available at Parkinson.org/PDGENEration.      

About the Parkinson’s Foundation

The Parkinson’s Foundation makes life better for people with Parkinson’s disease by improving care and advancing research toward a cure. In everything we do, we build on the energy, experience and passion of our global Parkinson’s community. Since 1957, the Parkinson’s Foundation has invested more than $449 million in Parkinson’s research and clinical care. Connect with us on Parkinson.org, Facebook, Twitter, Instagram or call 1-800-4PD-INFO (1-800-473-4636).

About Tasso

Tasso is an emerging healthcare technology company that is transforming the traditional blood collection paradigm with a patient-centric approach. The company’s devices enable simple, convenient, and virtually painless blood collection for users. Tasso technology has the power to bring healthcare anywhere, any time. Headquartered in Seattle, Washington, Tasso is privately held and funded by grants, investments, and co-development deals with various industry leaders. For more information, please visit www.tassoinc.com.

About Parkinson’s Disease

Affecting an estimated one million Americans, Parkinson’s disease is the second-most common neurodegenerative disease after Alzheimer’s and is the 14th-leading cause of death in the U.S. It is associated with a progressive loss of motor control (e.g., shaking or tremor at rest and lack of facial expression), as well as non-motor symptoms (e.g., depression and anxiety). There is no cure for Parkinson’s and nearly 90,000 new cases are diagnosed each year in the U.S.

Media Contacts

Parkinson’s Foundation

Melissa Nobles-Gonzalez

(305) 537-9134

mgonzalez@parkinson.org

Tasso, Inc

Dina Schneider

(206) 822-4186 x1016

media@tassoinc.com

Tasso Announces One Million Device Milestone

Last week we accomplished a huge milestone and shipped our one millionth device. This was an incredible moment for our company as a whole and something that was hard to imagine when we first started out nearly 12 years ago.

Our mission when we started was to make healthcare easy and accessible for everyone by bringing diagnostics to the home. When we shipped that millionth device, we recognized that it wasn't just a number or the parts, but also the million lives that we were able to touch with a completely new way of approaching diagnostics. We have received countless emails from people who have been able to access trials and programs that they haven't before due to disabilities or medical conditions, families that have been able to access blood testing for every member despite their fear of needles, and individuals who are looking for a better pathway to health than an inconvenient and painful phlebotomy visit. Each device we send helps us inch healthcare toward a preventive and proactive future.

I am incredibly grateful for all those who helped us get to where we are today. The team members with us and of past, the large scale partners and early ones who took a chance, the investors who have supported us in this journey, and the patients who keep us motivated every single day.

I am proud of what our team has accomplished and excited for the future that Tasso has in front of us. Onto the next million!

Ben Casavant, PhD

CEO & Co-Founder, Tasso, Inc.

Tasso Announces Launch of Tasso Care® for Prescreening

New full-service offering streamlines and accelerates clinical trial recruitment with patient-centric, scalable prescreening

SEATTLE – February 8th, 2024 – Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced the launch of Tasso Care® for Prescreening, an end-to-end services solution to maximize the success of a prescreening program. The new offering expands the foundation and expertise of the Tasso Care services platform in remote blood collection and analysis to support clinical trial recruitment.

Tasso Care for Prescreening is designed to support the prescreening of trial participants for a number of cardiometabolic and serostatus markers. Additional panels to support immunology, cardiovascular disease, and other therapeutic areas will launch as part of the prescreening platform throughout Q1 of 2024 as validation protocols are completed.

Screening participants is a major bottleneck for drug development, often leading to trial delays and high screen failure rates. Tasso Care revolutionizes the enrollment process by replacing time-consuming, labor-intensive clinic visits with convenient, automated prescreening testing at scale. By providing a virtually painless blood draw experience from home, Tasso drives higher clinical trial engagement rates by simplifying the operational process, optimizing the participants' blood collection experience, and ensuring a high-quality sample is returned to the lab.  Tasso Care enables large populations to be screened simultaneously anytime, anywhere, boosting trial access and diversity.

“Accelerating and expanding access to clinical trials is a key step toward improving healthcare,” said Ben Casavant, PhD, CEO and Co-Founder of Tasso. “Too often, trials experience enrollment delays due to the difficulty of identifying rare populations and obtaining up-to-date data. By making screening scalable and convenient, Tasso Care for Prescreening will empower programs to reach and recruit the right participants faster than ever.”

Tasso Care for Prescreening is intended for use under institutional review board (IRB)-reviewed prescreening protocols. To learn more about Tasso Care for Prescreening, please visit www.tassoinc.com/prescreening.

About Tasso

Tasso is an emerging healthcare technology company that is transforming the traditional blood collection paradigm with a patient-centric approach. The company’s devices enable simple, convenient, and virtually painless blood collection for users. Tasso technology has the power to bring healthcare anywhere, any time. Headquartered in Seattle, Washington, Tasso is privately held and funded by grants, investments, and co-development deals with various industry leaders. For more information, please visit www.tassoinc.com.

Media Contact

Dina Schneider

(206) 822-4186 x1016

media@tassoinc.com

2023 2H Business Update

In 2023, Tasso achieved remarkable growth driven by our unwavering focus on expanding access to care for more patients by offering convenient diagnostic healthcare options. Our patient-centric blood collection solutions have proven to be a valuable addition to the pharmaceutical and healthcare industry. Several new engagements forged in the second half of 2023 support our continued growth and ability to offer more complete solutions to the industry.  

As we head toward 2024, Tasso aims to remain at the forefront of a pivotal shift toward patient-centric, remote blood sample collection and decentralized clinical trials. We are excited to continue to expand and increase our capabilities as a new gateway to healthcare.

Tasso is dedicated to improving the patient experience with easily accessible diagnostics that help clinicians make better informed decisions about patient health. We deeply value every collaboration, whether these are commercial, community-centric or clinical in nature. Each one is critical to our growth and has helped Tasso expand our reach this year.

In 2024, we hope to continue these collaborations and find ways to offer novel, personalized diagnostic solutions to the marketplace.

2023 2H Business Highlights:

Expanding our Commercial Footprint

At Tasso, our mission is to improve patient experiences and health with expanded access to care. Growing our footprint across more regions and industries is critical to our success. Our recent certifications and new business relationships demonstrate our commitment to growth.

• We received CE Mark certification for the Tasso+® device, allowing us to offer patient-centric, high-volume blood collection solutions in the European Union (EU) market, including 28 member states, plus Iceland, Norway and Lichtenstein. The CE Mark designation ensures a product has met all European Commission safety, health and environmental protection requirements. With the CE Mark certification, Tasso+ now has achieved full clearance in the U.S. and the EU to sell devices, making it the first device of its kind to do so.

• We announced the successful completion of the System and Organization Controls (SOC) 2 Type 2 audit, providing compliance certification for our platform. The SOC 2 Type 2 audit is conducted by independent auditors to determine whether a company is maintaining a high standard for handling sensitive client data through its operations, controls, and processes. This achievement demonstrates our ability to securely manage client data and highlights our company’s commitment to meeting the highest industry standards.

• We announced a new engagement with Randox Health, which provides at-home and in-clinic health tests as part of Randox – the largest healthcare diagnostics company in the United Kingdom and Ireland – to offer at-home healthcare diagnostic testing powered by our innovative blood collection technology. Randox Health is the first major laboratory in the United Kingdom to validate the Tasso devices and offer them to consumers for at-home health and wellness diagnostic testing for individuals to make better informed decisions about their health.

• Our relationship with ZOE, a personalized nutrition company headquartered in the UK, will expand access to the Tasso+ blood collection device as part of a personalized nutrition program from the world’s largest nutrition-science study. By offering the Tasso+ device in its test kits, ZOE consumers will have access to virtually pain-free, efficient and simple blood sample collection – allowing them to incorporate data from certain biomarkers into their individualized nutrition program. 

Serving the Community Through Collaboration

Making testing accessible and convenient is key to supporting underserved populations. Tasso is proud to make life-changing care and research possible through our technology.

• Renegade.bio, an LGBTQ-owned public benefit corporation, announced that they will include Tasso devices as part of Renegade.bio’s at-home sexually transmitted infections (STI) testing kits. By offering Tasso devices, which allow convenient, virtually painless blood collection, Renegade.bio aims to increase access to STI testing, improve the patient experience, and reduce HIV and STI-related health disparities and inequities.

• Our technology contributed to the research success of the Million Veterans Program, a national research program looking at how genes, lifestyle, military experiences, and exposures affect health and wellness in Veterans. Since its launch in 2011, the program has accumulated 1 million veterans and has become the largest research effort at Veterans Affairs to improve health care for veterans.

Forging New Laboratory and Clinical Relationships

Tasso is synonymous with gold standard clinical quality. We choose to work with laboratories that share our passion for producing the best quality samples and data. These exciting new collaborations will expand what is possible using remote blood samples.

• Our new partnership with Quest Diagnostics, the leading provider of diagnostic information services, allows patients and healthcare providers access to Tasso’s convenient, easy-to-use and virtually painless blood collection devices. Through a series of collaborations, the partnership brings together Tasso’s innovative clinical-grade blood sample collection devices and end-to-end collection and analysis solutions with Quest’s world-class lab processing capabilities.

• Biodesix, a leading diagnostic solutions company with a focus in lung disease, is working with Tasso to create a new method for patients to collect blood specimens for Nodify Lung Nodule Risk Assessment testing using Tasso+.

Reaching New Milestones with Pharma

Tasso works closely with leaders across pharma to envision and develop the next generation of decentralized clinical trial solutions. We celebrated several milestones this year marking the adoption of Tasso technology for trials worldwide.

• Tasso is now working with 13 of the 15 largest pharmaceutical companies.

• Tasso devices have been used successfully in Phase I, Phase II, and Phase III clinical trials.

• New publications from Pfizer and Genentech highlighted the applications of Tasso’s devices for decentralized clinical trials.

Randox Health First to Offer Tasso’s Patient-Centric Remote Sampling Device

This partnership combines Randox Health’s expansive at-home testing capabilities with Tasso’s innovative and virtually painless blood sample collection solutions. 

November 28, 2023 – Randox Health, which provides at-home and in-clinic health tests as part of Randox – the largest healthcare diagnostics company in the UK and Ireland – and Tasso, Inc., the leading provider of patient-centric clinical-grade blood collection solutions, today announced a partnership to offer at-home healthcare diagnostic testing powered by Tasso’s innovative blood collection technology.

Randox Health offers more than 10 at-home testing kits for a variety of health concerns, and is the first major laboratory in the UK to validate the Tasso devices and offer them to consumers for at-home health and wellness diagnostic testing. Through the partnership, people using Randox Health at-home tests will have access to Tasso’s innovative portfolio of convenient, virtually painless blood collection device with pre-order availability for the device via their male & female hormone test kits in December.

“As part of our mission to transform preventative healthcare and enable consumers to take control of their health through quality data, we are thrilled to partner with Tasso to make it easier, more convenient and less painful for people to access critical health information,” said Alexander Rusak, Vice President of Sales at Randox Health. “By offering Tasso’s devices for clinical-grade blood sample collection as part of our testing kits – available through our website or at our clinic storefronts – we are providing an improved experience and addressing consumer needs.”

By combining Tasso’s technical expertise and Randox Health’s in-depth industry knowledge across key areas, including hormonal health, female health, genetics, and others, customers can benefit from receiving real-time insights about their health, enabling them to monitor and improve their overall well-being.

“Tasso and Randox Health share a vision of increasing access to healthcare with patient-centric solutions and accelerating convenient, at-home healthcare options,” said Ben Casavant, PhD, CEO and co-founder of Tasso, Inc. “By offering our devices as part Randox Health’s at-home testing kits, we hope to not only improve the patient experience, but also provide information that can allow individuals to make better informed decisions about their health.”

About Randox Health

Established in 1982, Randox is the largest healthcare diagnostics company from the UK & Ireland. Randox focusses on the provision of timely and accurate testing to identify risks to health, improve clinical diagnosis and promote preventative healthcare; aiming to achieve better healthcare outcomes, whilst reducing the burden on clinical services. Randox Health Clinics are based throughout the UK & Ireland, enabling easy-access for millions of people to a new range of preventative health packages designed to help clients take control of their health.

For more information, please visit randoxhealth.com

About Tasso

Tasso is an emerging healthcare technology company that is transforming the traditional blood collection paradigm with a patient-centric approach. The company’s devices enable simple, convenient, and virtually painless blood collection for users. Tasso technology has the power to bring healthcare anywhere, any time. Headquartered in Seattle, Washington, Tasso is privately held and funded by grants, investments, and co-development deals with various industry leaders. For more information, please visit www.tassoinc.com.

Media Contacts:

Lynsey Adams

Randox Health

marketing@randox.com

Dina Schneider

Tasso, Inc.

(206) 822-4186 x1016

media@tassoinc.com

Tasso Announces SOC 2 Type 2 Compliance Certification

Completion of SOC 2 Type 2 audit certifies Tasso platforms as trusted and secure

SEATTLE – October 27, 2023 – Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced the successful completion of the System and Organization Controls (SOC) 2 Type 2 audit. The SOC 2 Type 2 audit is conducted by independent auditors to determine whether a company is maintaining a high standard for handling sensitive client data through its operations, controls, and processes. The auditors observed Tasso’s operations against all five SOC 2 Trust Services Criteria (Security, Availability, Processing Integrity, Confidentiality, and Privacy) and found no exceptions. This achievement demonstrates Tasso’s ability to securely manage client data and highlights the company’s commitment to meeting the highest industry standards.

The SOC 2 Type 2 audit, which assesses the organization's controls over time, was completed in September of 2023. The audit was conducted by Prescient Assurance, a leader in security testing and compliance certifications for SaaS companies worldwide.

Tasso provides a variety of end-to-end blood collection logistics services as part of its Tasso Care™ solutions platform. Achieving SOC 2 Type 2 compliance, the industry gold standard, ensures that client data is safe and secure.

“This SOC 2 Type 2 compliance certification is an important milestone for Tasso,” said Ben Casavant, PhD, CEO and Co-Founder of Tasso. “Patient health and other sensitive data is critical to safeguard. Our SOC 2 report reemphasizes the security and privacy of our platform, and our commitment to protecting client data.”

About Tasso

Tasso is an emerging healthcare technology company that is transforming the traditional blood collection paradigm with a patient-centric approach. The company’s devices enable simple, convenient, and virtually painless blood collection for users. Tasso technology has the power to bring healthcare anywhere, any time. Headquartered in Seattle, Washington, Tasso is privately held and funded by grants, investments, and co-development deals with various industry leaders. For more information, please visit www.tassoinc.com.

Media Contact

Dina Schneider

(206) 822-4186 x1016

media@tassoinc.com

Tasso, Inc. Announces Monica Williams as Chief Financial Officer

Industry veteran brings decades of experience at high-growth technology companies

SEATTLE – September 28, 2023 – Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced the appointment of Monica Williams as Chief Financial Officer, reporting to Tasso’s CEO Ben Casavant.

Tasso’s signature line of virtually painless remote blood collection devices is available globally and demand continues to increase. Under Williams’ experienced leadership, Tasso is poised to grow rapidly.

“Monica is an experienced financial leader and brings a wealth of strategic growth knowledge to Tasso,” said Ben Casavant, PhD, CEO and co-founder of Tasso. "We are excited to have her join our team and drive our mission of growing Tasso to reach more patients.”

Williams brings to Tasso more than 20 years of experience in high-growth technology companies. She was CFO at Tango, Pro.com, Avvo and Allrecipes, and Vice President of FP&A and Treasury at Zillow Group. Williams holds a bachelor’s degree in finance and an MBA from the University of Washington and a Chartered Financial Analyst designation from the CFA Institute. 

“I am excited to join the mission-driven team at Tasso,” said Williams. “With innovative products and services that expand access and improve patient experiences, Tasso is making a positive impact on how health care is delivered. I look forward to partnering with the team and driving Tasso’s continued growth.”

About Tasso

Tasso is an emerging healthcare technology company that is transforming the traditional blood collection paradigm with a patient-centric approach. The company’s devices enable simple, convenient, and virtually painless blood collection for users. Tasso technology has the power to bring healthcare anywhere, any time. Headquartered in Seattle, Washington, Tasso is privately held and funded by grants, investments, and co-development deals with various industry leaders. For more information, please visit www.tassoinc.com.

Media Contact

Dina Schneider

(206) 822-4186 x1016

media@tassoinc.com

Tasso Receives CE Mark Certification for Tasso+™, Latest Generation Whole Blood Collection Lancet Device

Designation expands the availability of Tasso’s patient-centric blood collection solution for decentralized clinical trials, home diagnostic testing, wellness and anti-doping uses to the European Union

SEATTLE – September 19, 2023 – Tasso, Inc., the leading provider of patient-centric clinical-grade blood collection solutions, today announced it received CE Mark certification for its Tasso+™ device, a convenient, virtually pain-free blood lancet that collects whole liquid blood samples. The CE Mark designation allows Tasso to offer its patient-centric, high-volume blood collection solution in the European Union (EU) market, which includes 28 member states, plus Iceland, Norway and Lichtenstein. The CE Mark designation ensures a product has met all European Commission safety, health and environmental protection requirements.

The Tasso+ device received Class II 510(k) clearance from the U.S. Food and Drug Administration (FDA) in August 2022. With the CE Mark certification, Tasso+ now has achieved full clearance in the U.S. and the EU, making it the first device of its kind to do so.

“This designation is an important milestone for Tasso, allowing us to build upon the success of our CE Marked Tasso-M20 device and continue to expand our commercial footprint and reduce healthcare access barriers in Europe, where demand increasingly grows for patient-centric solutions,” said Ben Casavant, PhD, CEO and co-founder of Tasso. “The Tasso+ CE Mark enables us to support the pharmaceutical industry, academic and government institutions on research and clinical initiatives, as well as accelerate access to remote testing and care for more patient populations. We are excited to expand our customer base in Europe.”

The Tasso+ device is a single-use blood lancing device for obtaining microliter capillary whole blood samples. Based on groundbreaking technology, Tasso+ allows for virtually painless blood samples to be collected remotely, with a user-friendly interface that boosts satisfaction and engagement.

The device can be used with compatible collection tubes to accelerate decentralized clinical trials for pharmaceutical companies, especially for pharmacokinetic and biomarker research endpoints. With a patient-centric collection process that overcomes care access barriers, Tasso+ enables underserved and understudied patient populations to participate in clinical trials. In addition, healthcare systems and physicians can use the Tasso+ device to make determinations on blood chemistries for their patients and expand access to care.

About Tasso

Tasso is an emerging healthcare technology company that is transforming the traditional blood collection paradigm with a patient-centric approach. The company’s devices enable simple, convenient, and virtually painless blood collection for users. Tasso technology has the power to bring healthcare anywhere, any time. Headquartered in Seattle, Washington, Tasso is privately held and funded by grants, investments, and co-development deals with various industry leaders. For more information, please visit www.tassoinc.com.

###

Media Contact

Dina Schneider

Tasso, Inc.

(206) 822-4186 x1016

media@tassoinc.com

Partner News: Artyc Launches Medstow Mini for Temperature Stable Blood Sample Collection and Delivery

SAN FRANCISCO, September 12th, 2023 – Artyc PBC, a California-based cold chain startup, announced today the launch of Artyc’s Medstow Mini, a small battery-powered cooling container designed to transport medical goods through the supply chain.

The Medstow Mini is a reusable active temperature stabilization and cooling container for shipping blood samples, blood vials, and cells collected within the home or clinical settings. The Medstow Mini can withstand varying ambient temperatures, prevent temperature excursions, and provide live data insights on location and temperature of samples via a user-friendly app.

Artyc entered a joint development program for the Medstow Mini with Tasso Inc., the leading provider of patient-centric clinical-grade blood collection solutions, to develop a logistics solution that supports the temperature-controlled delivery of high-quality decentralized blood testing solutions for the pharmaceutical industry. Leveraging Tasso’s end-to-end integrated logistics platform to support shipping, participant engagement and more, the Medstow Mini is designed to meet the needs of next-generation at-home sample collection and remote diagnostics to ensure both accuracy and regulatory compliance for customers.

“With the launch of the Medstow Mini, Artyc is taking a first step towards building a sustainable cold chain,” said Hannah Sieber, co-founder and CEO of Artyc. “The Medstow Mini allows our customers to increase healthcare access, reduce packaging waste, and slash cold chain emissions. In partnership with Tasso, we’re excited to offer a novel solution for shipments of at-home diagnostics.”

Historically, global supply chains have relied on cold chain infrastructure such as refrigerated trucks, cold rooms, and cold packs to keep products at stable temperatures. Yet, these transport systems and cooling technologies are energy, capital and labor intensive, often leading to a lack of tight temperature regulation and visibility and resulting in sample spoilage and excessive cold chain waste

“We are excited to see new technologies such as those from Artyc being developed to provide the highest level of control over blood sample logistics,” said Erwin Berthier, co-founder and CTO of Tasso. “Bringing diagnostics to the home will provide access to an essential component of healthcare to many underserved patients but will require new solutions that ensure the integrity of samples and an efficient, safe and seamless shipping process. Through our collaboration, Artyc is in a position to be a leader in this space.”

At every stage of transport, from source to destination, Artyc’s Medstow Mini ensures product integrity by controlling, monitoring and reporting temperatures. This feature set is crucial for medical logistics; when transporting blood, for example, specimens must be stored at refrigerated temperatures between +2 and +8 degrees Celsius at all times. Prolonged excursion outside of this temperature range will spoil the sample. By electrifying the cold chain, Artyc provides precision temperature control for days rather than hours and offers a solution that is both reusable and rechargeable for sustainable logistics.

The Artyc Medstow Mini is the first of a suite of products to be launched by Artyc that are purpose-built for the medical industry. The company is developing additional products for other industries which require a cold supply chain, such as food and agriculture.

June 2023 Business Update

Ben Casavant, PhD

CEO & Co-Founder, Tasso, Inc.

Tasso has continued to experience tremendous growth in 2023, fueled by new and expanded partnerships and increased demand for our patient-centric blood collection solutions. With our focus on expanding access to care for more patient populations, accelerating convenient at-home healthcare options and paving the way for a pivotal shift toward decentralized clinical trials, we continued to expand our capabilities and footprint, solidify partnerships and gain market traction.

Notably, we recently announced new collaborations with Aptar Digital Health, CardioRenal and United BioSource LLC (UBC) to support decentralized blood collection for research and real-world evidence generation. Our collaborations with these key partners are critical to our momentum and growth within the pharmaceutical and healthcare landscape. They share our mission of providing patient friendly health data services that improve patient retention and compliance and boost patient engagement, with the ultimate goal of bringing diagnostic testing to the home to improve patient experience and health.

2023 Business Highlights:

• We received our Medical Device Single Audit Program (MDSAP) certification, confirming our compliance with the standards and regulatory requirements of Australia, Canada and the United States. This was a critical step forward in offering our blood collection solutions for decentralized clinical trials and home diagnostic testing to additional global markets. The certification also will streamline the process of reaching other markets covered under the MDSAP, including Brazil and Japan.

• Our most recent partnership is with UBC, a leading provider of evidence development solutions for the biopharmaceutical industry. Through the partnership, we will collaborate on efficient, streamlined, and convenient sample collection and analysis solutions for post-approval research. Tasso and UBC have already been awarded a late-stage biomarker monitoring study, with additional projects in the funnel.

• We entered into a collaboration with Aptar Digital Health earlier this month that will offer access to Tasso’s devices for blood collection to Aptar Digital Health end-users. The alliance accelerates a decentralized approach to blood collection and will reduce patient burden related to laboratory testing. Tasso blood collection devices will be available to patients who participate in Aptar Digital Health randomized-clinical trials and real-world studies, as well as to life science companies with whom Aptar Digital Health partners to develop digital health solutions, such as digital therapeutics, disease management platforms and digital patient support programs.

• Our new partner, CardioRenal, a pioneer in the remote treatment of patients with severe chronic kidney disease (CKD), obtained Breakthrough Device Designation from the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA) for its TENOR device in May. TENOR is a connected medical device to assist patients with chronic illnesses, including CKD, in measuring their blood potassium levels at home. Through our partnership, patients will collect blood for potassium analysis at home using Tasso+, a convenient, easy-to-use, virtually pain-free blood collection device. The partnership will allow us to demonstrate how our blood collection device can be used in combination with the TENOR system to remotely access data for CKD.

Tasso and UBC Partner to Advance Decentralized Sample Collection and Analysis Solutions for Post-Approval Research

Seattle and Blue Bell, P.A., June 27, 2023 – Tasso, Inc., the leading provider of patient-centric clinical-grade blood collection solutions, and United BioSource LLC (UBC), a leading provider of evidence development solutions for the biopharmaceutical industry, today announced a partnership to provide more efficient, streamlined, and convenient sample collection and analysis options for post-approval research to improve study design and enable a better patient experience.

The new partnership will bring together Tasso’s devices for at-home, virtually painless clinical-grade blood sample collection and end-to-end collection and analysis solutions with UBC’s late-stage research expertise in evidence development and participant support services, including digital recruitment and engagement strategies, powerful real-world data infrastructure and rapid analytics software. Together, the two companies will offer a complete solution for biopharmaceutical companies seeking to improve participant retention and compliance, boost patient engagement, and enroll more diverse patient populations in decentralized post-approval studies.

Tasso and UBC have recently been awarded a late-stage biomarker monitoring study, with additional projects expected to follow.

“This collaboration combines UBC’s expertise in modernized study design and execution with our innovative offerings to create an unprecedented new solution for patient-centric, decentralized research,” said Ben Casavant, PhD, CEO and co-founder of Tasso, Inc. “Importantly, the collaboration will not only provide sponsors with the high-quality data they require but will also drive much-needed improvement in the patient experience and trial participant diversity.”

Research utilizing the joint offering will be powered by Tasso’s integrated solutions to streamline blood sample collection and analysis. After sponsors provide a list of samples needed, Tasso will handle shipping at-home blood collection kits directly to research participants, manage transport of samples to an analytical laboratory that has validated the specific test(s) needed, and communicate lab results back to the sponsor. The fully integrated Tasso Connect portal will ensure samples can be tracked with out-of-the-box functionality, and for seamless connectivity, partners can link with their own systems through Tasso’s API integration.

“With today’s rapidly evolving post-approval drug development requirements, there’s a real need to help sponsors efficiently, effectively, and safely execute and manage late-stage and real-world evidence generation research programs that meet regulatory and payer requirements and support their product commercialization objectives,” said Aaron Berger, Head of Evidence Development, UBC. “Our partnership with Tasso allows us to collectively provide flexible, integrated and innovative offerings that improve the patient experience and advance decentralized research methods.”

About Tasso

Tasso is an emerging healthcare technology company that is transforming the traditional blood collection paradigm with a patient-centric approach. The company’s devices enable simple, convenient, and virtually painless blood collection for users. Tasso technology has the power to bring healthcare anywhere, any time. Headquartered in Seattle, Washington, Tasso is privately held and funded by grants, investments, and co-development deals with various industry leaders. For more information, please visit www.tassoinc.com.

About UBC

United BioSource LLC (UBC) is the leading provider of evidence development solutions with an expertise in unifying evidence and access. UBC helps biopharma mitigate risk, address product hurdles, and demonstrate safety, efficacy, and value under real-world conditions. Underpinned by our scientific expertise, data and analytics, and innovative technologies, we offer our customers flexible solutions generating the relevant real-world data necessary to make more informed decisions earlier, meet stakeholder requirements, and, ultimately, drive better patient outcomes. For additional information, visit www.ubc.com.

###

Media Contact:

Dina Schneider

Tasso, Inc.

(206) 822-4186 x1016

media@tassoinc.com

Amber Frasketi

UBC

(215) 588-8423

amber.frasketi@ubc.com